CytRx, Qiagen, Sirna, CIC bioGUNE, Open Biosystems, Upstate, Galapagos, Devgen, DuPont | GenomeWeb

CytRx Unable to File Q1 Results on Schedule

CytRx said this week that it is unable to file its first-quarter financial results with the US Securities and Exchange Commission on schedule.

In an SEC filing, CytRx said it is unable to file the report "due to its further review and assessment … of the company's stock options and possible adjustments to the pro forma disclosures in the stock-based compensation footnote to the company's financial statements."

CytRx did not provide an estimate as to when it would be able to file its financial results.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.